参考资料: [1] European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy. Retrieved October 16, 2023, from https://www.merck.com/news/european-commis...
2. Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for PatientsWith Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: ResultsFrom the Phase I KEYNOTE-001 Study. J Clin Oncol, Published online on 2 June,2019. DOI: 10.1200/JCO.19.00934. 3. KEYNOTE-189:...
原文出处:FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy https://www.mrknewsroom.com/news-release/preion-medicine...
Learn about an immunotherapy treatment option to help certain patients with non–small cell lung cancer. See clinical results here.
5.Herbst R S, Baas P, Kim D W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial[J]. The Lancet, 2016, 387(10027): 1540-1550. ...
1. Siegel RL, Miller KD, Jemal A.Cancer statistics, 2016. CA Cancer J Clin. 2016;66(1):7–30. 2. Reck M, Rodriguez-Abreu D,Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-celllung cancer....
[1]FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Therapy for Stage IB (≥4 centimeters)-IIIA Non-Small Cell Lung Cancer Following Complete Surgical Resection - Merck.com https://www.merck.com/news...
[1] Martin Reck, et al., (2021). Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%. Journal of Clinical Oncology, DOI: 10.1200/JCO.21.00174 [2] Lung Cancer Survival Continues to Rise With ...
FDA approves Merck’s KEYTRUDA® (pembrolizumab) in Combination with Carboplatin and Either Paclitaxel or Nab-Paclitaxel for the First-Line Treatment of Patients with Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) 我们特别建了“患者交流群”,欢迎肿瘤患者/家属扫描下方二维码,加入交流群,大家一...
[2] FDA Grants Priority Review to Merck’s Supplemental Biologics License Application for KEYTRUDA® (pembrolizumab) Monotherapy for Third-Line Treatment of Patients with Advanced Small Cell Lung Cancer (SCLC). Retrieved April 10, 2019, fromhttps://www.businesswire.com/news/home/20190220005296/en...